Literature DB >> 20227542

Clinical pharmacokinetics and interaction of centchroman--a mini review.

Jawahar Lal1.   

Abstract

This article provides a brief review of the information available regarding the published pharmacokinetics data for the nonsteroidal, once-a-week oral contraceptive, centchroman (INN: ormeloxifene). This agent is a unique need-oriented contraceptive agent which is included in the National Family Welfare Programme of India. Since 1991, centchroman has been used as a need-oriented contraceptive and is being given for treating dysfunctional bleeding of the uterus. Information regarding absorption, tissue distribution, elimination and kinetic interactions is discussed. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20227542     DOI: 10.1016/j.contraception.2009.11.007

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  14 in total

1.  On the pill.

Authors:  Ellen Friedrichs
Journal:  Nat Med       Date:  2010-05       Impact factor: 53.440

2.  Effectiveness of Centchroman on Regression of Fibroadenosis and Mastalgia.

Authors:  Udayakumar Rajswaroob; Rajendiran Kannan; Narayanasamy Subbaraju Kannan; T Tirouaroul
Journal:  J Clin Diagn Res       Date:  2016-10-01

3.  A study of efficacy of ormeloxifene in the pharmacological management of dysfunctional uterine bleeding.

Authors:  Komaram Ravibabu; Jayasree Palla; Ganapathi Swamy Chintada
Journal:  J Clin Diagn Res       Date:  2013-11-10

4.  Effect of arteether and pyrimethamine coadministration on the pharmacokinetic and pharmacodynamic profile of ormeloxifene.

Authors:  Abhisheak Sharma; Swati Jaiswal; Mahendra Shukla; Jawahar Lal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-07-08       Impact factor: 3.000

5.  Centchroman regresses mastalgia: a randomized comparison with danazol.

Authors:  Prakash Lakhmichand Tejwani; Anurag Srivastava; Hrishikesh Nerkar; Anita Dhar; Smriti Hari; Sanjay Thulkar; Sunil Chumber; Sunesh Kumar
Journal:  Indian J Surg       Date:  2010-11-30       Impact factor: 0.656

6.  The role of sevista in the management of dysfunctional uterine bleeding.

Authors:  Dhananjay Bs; Sunil Kumar Nanda
Journal:  J Clin Diagn Res       Date:  2012-09-10

Review 7.  Anti-cancer potential of a novel SERM ormeloxifene.

Authors:  Rishi Kumar Gara; Vasudha Sundram; Subhash C Chauhan; Meena Jaggi
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

8.  Ormeloxifene efficiently inhibits ovarian cancer growth.

Authors:  Diane M Maher; Sheema Khan; Jordan L Nordquist; Mara C Ebeling; Nichole A Bauer; Lucas Kopel; Man Mohan Singh; Fathi Halaweish; Maria C Bell; Meena Jaggi; Subhash C Chauhan
Journal:  Cancer Lett       Date:  2014-10-13       Impact factor: 8.679

9.  Polyphenols sensitization potentiates susceptibility of MCF-7 and MDA MB-231 cells to Centchroman.

Authors:  Neetu Singh; Deeba Zaidi; Hari Shyam; Ramesh Sharma; Anil Kumar Balapure
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

10.  Design and synthesis of chroman derivatives with dual anti-breast cancer and antiepileptic activities.

Authors:  Pinki Rawat; Saurabh Manaswita Verma
Journal:  Drug Des Devel Ther       Date:  2016-09-02       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.